A progressive and painless pink pimple A man presents with a painless nodule in his arm that developed over recent a few months. What dermoscopic features are helpful in diagnosing this lesion? Case presentation A 63-year-old office worker presented with a painless nodule on his correct higher arm that had arisen lately. The lump was not present five months earlier when he attended for his latest full skin examination. He had fair skin with many solar lentigines, moderate amounts of actinic keratoses and few naevi, non-e of which were dysplastic. There was a past background of three nonmelanoma pores and skin cancers, all on sun-exposed sites, and a grouped genealogy of melanoma affecting his mother..Ockene, Ph.D., Dorothy S. Lane, M.D., Gloria E. Sarto, M.D., Aleksandar Rajkovic, M.D., Ph.D., Robert Schenken, M.D., Susan L. Hendrix, D.O., Peter M. Ravdin, M.D., Ph.D., Thomas E. Rohan, M.B., B.S., Ph.D., Shagufta Yasmeen, M.D., and Garnet Anderson, Ph.D. For the WHI Investigators: Breast Tumor after Usage of Estrogen plus Progestin in Postmenopausal Women The Women’s Health Initiative trial of conjugated equine estrogens plus medroxyprogesterone acetate was stopped when health risks were shown to exceed the advantages of combined hormone therapy.1 The incidence of breasts cancer was higher in the hormone-therapy group, and the cancers were larger and more advanced2; furthermore, the frequency of abnormalities on mammograms and of breast biopsies was improved in the hormone-therapy group.3 After the release of our initial WHI report, in 2002,1 menopausal hormone use decreased in the United States considerably.4,5 Approximately a year later, a considerable drop in the incidence of breasts cancer was observed.6,7 Although several countries subsequently reported similar decreases,8-10 others did not,11,12 and the reason for the decline continues to be controversial.13,14 The temporal relation between decreased use of menopausal hormones and the drop in the incidence of breast cancer suggested causality, although changes in the frequency of mammographic screening as well as other factors were recognized as possible contributors.6,7 When the WHI trial was stopped, more breasts cancers were observed in the follow-up period among women who had received estrogen in addition progestin than in the placebo group,15 and it appeared that hormone therapy hindered the recognition of breast cancer.2,3 Methods Details of the WHI study have already been described elsewhere.16-18 Briefly, postmenopausal females between the ages of 50 and 79 years with an anticipated survival of in least three years were eligible.